BACKGROUND: Studies investigating the molecular basis of psoriasis have established the central roles of TNFa, interleukin (IL)-12, IL-22 and IL-23, and now there is increasing evidence that IL-17 plays a vital role in the complex pathophysiology of this disease. Preclinical and phase II studies of medications targeting IL-17 and its receptor have thus far proved to be promising. METHODS: We reviewed the results of the phase III clinical trials for the anti-IL-17 agents secukinumab, ixekizumab and brodalumab in order to assess the efficacy and safety profile of each agent. RESULTS: By week 12, the proportion of patients reaching a 75% improvement from baseline Psoriasis Area and Severity Index (PASI 75) was comparable between the different agents (secukinumab 83%, ixekizumab 89%, and brodalumab 85%). The safety profiles of the agents were similar with the most frequently reported adverse events of nasopharyngitis, upper respiratory infections, headache, and injection site reaction. CONCLUSION: The anti-IL-17 agents demonstrated a rapid and robust clinical improvement accompanied by a favorable short-term safety profile. The results of the phase III trials continue to reinforce the theory that the IL-17 pathway is an essential target in psoriasis treatment.
BACKGROUND: Studies investigating the molecular basis of psoriasis have established the central roles of TNFa, interleukin (IL)-12, IL-22 and IL-23, and now there is increasing evidence that IL-17 plays a vital role in the complex pathophysiology of this disease. Preclinical and phase II studies of medications targeting IL-17 and its receptor have thus far proved to be promising. METHODS: We reviewed the results of the phase III clinical trials for the anti-IL-17 agents secukinumab, ixekizumab and brodalumab in order to assess the efficacy and safety profile of each agent. RESULTS: By week 12, the proportion of patients reaching a 75% improvement from baseline Psoriasis Area and Severity Index (PASI 75) was comparable between the different agents (secukinumab 83%, ixekizumab 89%, and brodalumab 85%). The safety profiles of the agents were similar with the most frequently reported adverse events of nasopharyngitis, upper respiratory infections, headache, and injection site reaction. CONCLUSION: The anti-IL-17 agents demonstrated a rapid and robust clinical improvement accompanied by a favorable short-term safety profile. The results of the phase III trials continue to reinforce the theory that the IL-17 pathway is an essential target in psoriasis treatment.
Authors: Ryan Rivera-Oyola; Roselyn Stanger; Graham H Litchman; Quinn Thibodeaux; John Koo; Richard Fried; Gary Goldenberg; George Han; Sylvia Hsu; Leon Kircik; Melissa Knuckles; Andrea Murina; Jeffrey Weinberg; Jashin J Wu; Mark Lebwohl Journal: J Clin Aesthet Dermatol Date: 2020-12-01
Authors: Linghui Xu; Wanhong Ding; Lori L Stohl; Xi K Zhou; Shayan Azizi; Ethan Chuang; Jimmy Lam; John A Wagner; Richard D Granstein Journal: Immunology Date: 2017-12-20 Impact factor: 7.397
Authors: Alexandra Zanin-Zhorov; Jonathan M Weiss; Alissa Trzeciak; Wei Chen; Jingya Zhang; Melanie S Nyuydzefe; Carmen Arencibia; Seetharam Polimera; Olivier Schueller; Judilyn Fuentes-Duculan; Kathleen M Bonifacio; Norma Kunjravia; Inna Cueto; Jennifer Soung; Roy M Fleischmann; Alan Kivitz; Mark Lebwohl; Margarita Nunez; Johnnie Woodson; Shondra L Smith; Robert F West; Mark Berger; James G Krueger; John L Ryan; Samuel D Waksal Journal: J Immunol Date: 2017-04-07 Impact factor: 5.422
Authors: Andris Zeltins; Jonathan West; John Foerster; Martin F Bachmann; Franziska Zabel; Aadil El Turabi; Ina Balke; Stefanie Haas; Melanie Maudrich; Federico Storni; Paul Engeroff; Gary T Jennings; Abhay Kotecha; David I Stuart Journal: NPJ Vaccines Date: 2017-10-23 Impact factor: 7.344